Tempest Therapeutics
TPST
92 hedge funds and large institutions have $745M invested in Tempest Therapeutics in 2015 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 43 increasing their positions, 16 reducing their positions, and 16 closing their positions.
341% more call options, than puts
Call options by funds: $35.9M | Put options by funds: $8.15M
169% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
7% more funds holding
Funds holding: 86 → 92 (+6)
6% less capital invested
Capital invested by funds: $796M → $745M (-$51.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$24.5M |
| 2 |
GTP
Global Thematic Partners
New York
|
+$17.2M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$17.1M |
| 4 |
OH
Orbis Holdings
Hamilton,
Bermuda
|
+$11.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$53.9M |
| 2 |
DM
Deerfield Management
New York
|
-$14.1M |
| 3 |
Morgan Stanley
New York
|
-$7.51M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.6M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$3.3M |
TPST Hedge Fund Activity: Q2 2015 in Review
92 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2015, worth a combined $745M — down 6.5% from $796M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TPST positions and 16 closed out — a net gain of 6 holders — while 43 added to existing stakes and 16 trimmed.
The largest buyer was Jennison Associates, adding an estimated $24.5M. The largest seller was Sabby Management, cutting an estimated $53.9M.
- 92 institutional investors held Tempest Therapeutics (TPST) as of Q2 2015, up from 86 in Q1 2015.
- Funds reported $745M of Tempest Therapeutics stock for Q2 2015, down 6.5% quarter-over-quarter.
- 22 funds opened new Tempest Therapeutics positions in Q2 2015 and 16 closed out, a net change of +6 holders.
- The largest Tempest Therapeutics buyer in Q2 2015 was Jennison Associates, an estimated $24.5M added.
- The largest Tempest Therapeutics seller in Q2 2015 was Sabby Management, an estimated $53.9M sold.
Based on aggregated 13F filings for Q2 2015.